The enzyme 11b-hydroxysteroid dehydrogenase type 2 (11b-HSD2) has an essential role in aldosterone target tissues, conferring aldosterone selectivity for the mineralocorticoid receptor (MR) by converting 11b-hydroxyglucocorticoids to inactive 11-ketosteroids. Congenital deficiency of 11b-HSD2 causes a form of salt-sensitive hypertension known as the syndrome of apparent mineralocorticoid excess. The disease phenotype, which ranges from mild to severe, correlates well with reduction in enzyme activity. Furthermore, polymorphisms in the 11b-HSD2 coding gene (HSD11B2) have been linked to high blood pressure and salt sensitivity, major cardiovascular risk factors. 11b-HSD2 expression is controlled by different factors such as cytokines, sex steroids, or vasopressin, but posttranslational modulation of its activity has not been explored. Analysis of 11b-HSD2 sequence revealed a consensus site for conjugation of small ubiquitin-related modifier (SUMO) peptide, a major posttranslational regulatory event in several cellular processes. Our results demonstrate that 11b-HSD2 is SUMOylated at lysine 266. Non-SUMOylatable mutant K266R showed slightly higher substrate affinity and decreased V max , but no effects on protein stability or subcellular localization. Despite mild changes in enzyme activity, mutant K266R was unable to prevent cortisol-dependent MR nuclear translocation. The same effect was achieved by coexpression of wild-type 11b-HSD2 with sentrin-specific protease 1, a protease that catalyzes SUMO deconjugation. In the presence of 11b-HSD2-K266R, increased nuclear MR localization did not correlate with increased response to cortisol or increased recruitment of transcriptional coregulators. Taken together, our data suggests that SUMOylation of 11b-HSD2 at residue K266 modulates cortisol-mediated MR nuclear translocation independently of effects on transactivation. Abbreviations: 11b-HSD1, 11b-hydroxysteroid dehydrogenase type 1; 11b-HSD2, 11b-hydroxysteroid dehydrogenase type 2; AME, apparent mineralocorticoid excess; ANOVA, analysis of variance; CFP, cyan fluorescent protein; DMEM, Dulbecco's modified Eagle medium; EC 50 , 50% effective concentration; FBS, fetal bovine serum; GAPDH, glyceraldehyde 3-phosphate dehydrogenase; GFP, green fluorescent protein; GR, glucocorticoid receptor; GRE, glucocorticoid response element; HA, hemagglutinin; HPLC, high-performance liquid chromatography; LC-MS/MS, liquid chromatographytandem mass spectrometry; MR, mineralocorticoid receptor; NAD, nicotinamide adenine dinucleotide; PLA, proximity ligation assay; SE, standard error; SENP1, sentrin-specific protease 1; SRC-1, steroid receptor coactivator 1; SUMO, small ubiquitin-related modifier; WT, wild-type; YFP, yellow fluorescent protein.
to inactive cortisone (2) . The reverse reaction is NAD phosphate-dependent and is catalyzed by the isozyme 11b-HSD type 1 (11b-HSD1), leading to increased local cortisol concentration in tissues such as liver and adipose (3, 4) . 11b-HSD2 is specifically expressed in aldosterone target tissues, such as epithelial cells from distal colon and principal cells of the distal nephron, and serves to protect the nonselective mineralocorticoid receptor (MR) from activation by glucocorticoids, which circulate at much higher concentration than aldosterone. 11b-HSD2 confers aldosterone specificity on MR and brings key physiological functions of electrolyte and volume homeostasis under the control of the renin-angiotensin system (4) .
11b-HSD2 can be saturated by high cortisol levels due to cortisol hypersecretion, resulting in inappropriate MR activation (5, 6) . Similarly, decreased 11b-HSD2 activity also leads to inappropriate activation of MR by endogenous glucocorticoids. In both situations, MR target proteins, such as the epithelial sodium channel, are uncoupled from the renin-angiotensin system, leading to renal sodium retention and a salt-sensitive increase in blood pressure, both in humans (7) and in rodent models (8) (9) (10) . This concept is illustrated by the syndrome of apparent mineralocorticoid excess (AME), characterized by hypertension, hypokalemia, and low renin and aldosterone levels (11) . AME can be congenital, due to lossof-function mutations of the 11b-HSD2 coding gene (HSD11B2) (12) , or acquired, most commonly due to excessive consumption of natural licorice, which contains glycyrrhetinic acid that together with its derivative, carbenoxolone, inhibit 11b-HSD2 (13) . In patients, the severity of AME symptoms correlates well with the underlying enzyme activity (14) . Several polymorphisms in HSD11B2 correlate with slightly decreased 11b-HSD2 activity and associate to salt-sensitive increase of blood pressure both in healthy volunteers and patients with essential hypertension (15) (16) (17) (18) (19) (20) (21) . This evidence indicates that appropriate control of 11b-HSD2 expression and activity is essential for blood pressure regulation (22) . Factors controlling 11b-HSD2 expression are not fully defined, although there is evidence indicating transcriptional regulation by cytokines, sex steroids, vasopressin, and microRNAs (1, 23) . However, cellular mechanisms that dynamically regulate 11b-HSD2, such as posttranslational modifications, have not been explored.
Small ubiquitin-related modifiers (SUMOs) are ;11-kDa polypeptides that are posttranslationally conjugated to other proteins. This reversible posttranslational modification is typically observed in nuclear proteins, related to transcription factor regulation (24) , DNA damage response (25) , mitosis, or cell cycle progression (26) . However, regulatory SUMOylation has also been described in cytosolic or plasma membrane proteins (27) . Analysis of the human 11b-HSD2 sequence uncovered a canonical SUMOylation consensus motif around lysine 266 (Fig. 1) . Based on that, we hypothesized that SUMOylation of K266 in 11b-HSD2 may be involved in regulating enzyme activity and therefore could affect MR glucocorticoid-dependent transcriptional activity. Our results show that 11b-HSD2 is SUMOylated at residue K266. Non-SUMOylatable mutant 11b-HSD2, K266R, displays mild changes in enzymatic activity with slightly higher affinity but decreased V max and is unable to prevent cortisol-dependent MR nuclear translocation. Paradoxically, increased MR nuclear localization in the presence of 11b-HSD2-K266R does not correlate with enhanced activity in the presence of cortisol. Our results uncover a prominent role of 11b-HSD2 SUMOylation in controlling cortisol-dependent MR subcellular localization.
Materials and Methods

Sequence analysis
We used the prediction algorithm GPS-SUMO (28) to search for consensus SUMOylation motifs (c-K-x-D/E, where c is a large hydrophobic residue, K is the lysine conjugated to SUMO, x is any amino acid, and D or E is an acidic residue -Asp or Glu-) in 11b-HSD2 from different species. Additionally, GPS-SUMO was used to predict putative SUMO interaction motifs in the same sequences. Multiple sequence comparison was performed with Clustal Omega (European Bioinformatics Institute, Hinxton, UK).
Plasmid constructs
Generation and use of functional fluorescent derivatives of MR with insertion of yellow fluorescent protein (YFP) or green fluorescent protein (GFP) after amino acid 147 (MR-147-YFP/GFP) has been previously described (29) (30) (31) . Plasmid pcDNA3.1-MR, expressing hMR-wild-type (WT), was previously described (32) . Plasmid expressing WT human 11b-HSD2 fused to FLAG epitope (11b-HSD2-FLAG) cloned in pcDNA3 (Invitrogen/Thermo Fisher Scientific, Waltham, MA) has been previously described (33) . 11b-HSD2 coding sequence was amplified by polymerase chain reaction and subcloned in peCFP-N1 vector (Clontech, Mountain View, CA) to produce an in-frame fusion with the cyan fluorescent protein (CFP) (11b-HSD2-CFP). 11b-HSD2 non-SUMOylatable mutant K266R and AME mutants R337C (34) or R213C (35) were obtained upon introducing point mutations by sitedirected mutagenesis using the QuickChange Lightning kit (Agilent Technologies, Santa Clara, CA). Human SUMO1 cloned in pEYFP-C1 (Clontech) to express YFP-SUMO1 was a gift from Dr. Edward Yeh (Addgene, Cambridge, MA; plasmid 13380) (36) . Sequence of human deSUMOylase sentrin-specific protease 1 (SENP1) cloned in pFlag-CMV (Sigma-Aldrich, St. Louis, MO) to express epitope-tagged FLAG-SENP1 was obtained from Addgene collection (plasmid 17357) (37) . SENP1 sequence was amplified by polymerase chain reaction and subcloned in pcDNA 3.1 (Invitrogen) to remove the FLAG epitope from the original construct to prevent cross-reactions in proximity ligation assays (PLAs). Generation of a plasmid expressing hemagglutinin (HA)-tagged steroid receptor coactivator 1 (SRC-1) has been previously described (29) . All constructs and mutations were confirmed by DNA sequencing.
Cell culture, transfection, and hormone treatment
We used COS-7 cells, which lack endogenous MR and glucocorticoid receptor (GR) expression (38) . COS-7 cells were obtained from American Type Culture Collection (Manassas, VA) and maintained in Dulbecco's modified Eagle medium (DMEM) supplemented with 10% fetal bovine serum (FBS). Cells were regularly tested to ensure absence of mycoplasma infection. Cells were transfected with jetPRIME (Polyplus Transfection, Illkirch, France) as described before (29, 30) . pcDNA3.1 (Invitrogen) was used as a control in transfections. At the time of transfection, cells were washed and transferred to growth medium supplemented with charcoal-stripped FBS (Lonza, Basel, Switzerland) to eliminate steroids. Twenty-four hours after transfection, cells were washed and treated with the indicated amounts of aldosterone or cortisol. Aldosterone and cortisol were obtained from Sigma-Aldrich, dissolved in ethanol, and added to cells to the final concentration indicated for each experiment. Control cells were treated with ethanol at the same dilution used for treatments (1:1000).
Immunoprecipitation and western blot analysis
Immunoprecipitation of 11b-HSD2 was performed using a mouse monoclonal antibody against FLAG epitope (SigmaAldrich) at 1:150 dilution in lysis buffer [170 mM NaCl, 1 mM EDTA, 1 mM dithiothreitol, 20 mM Tris-HCl (pH 7.6)] supplemented with 0.5% Nonidet P-40 and a protease inhibitor cocktail (Roche, Basel, Switzerland) ( Table 1) . Antibodyantigen complex capture was performed using proteome protein A and protein G magnetic beads kit (Millipore, Billerica, MA). Western blot analysis was performed as previously described (29, 30) . Human 11b-HSD2 was detected with rabbit polyclonal antibody (H-145; Santa Cruz Biotechnology, Santa Cruz, CA; epitope corresponding to amino acids 261-405). MR was detected with mouse monoclonal antibody rMR365-4D6, developed by Gomez-Sanchez et al. (39) and obtained from the Developmental Studies Hybridoma Bank (University of Iowa, Department of Biology, Iowa City, IA). When indicated, fluorescent fusion proteins were detected using a polyclonal antibody raised in rabbit (Abcam, Cambridge, UK), provided by Dr. Raimundo Freire (40) . To control for total protein loading we used monoclonal antibodies against glyceraldehyde 3-phosphate dehydrogenase (GAPDH; Abcam) or b-actin (Sigma-Aldrich). Secondary antibodies conjugated with peroxidase (GE Healthcare, Chicago, IL) were used at 1:10,000 dilution. Western blots were developed with an Immun-Star WesternC kit (Bio-Rad, Hercules, CA), and signals were detected with a Chemidoc imaging system (Bio-Rad) and quantified with the software provided by the manufacturer (Image Laboratory, Bio-Rad).
Cell imaging and kinetic analysis of nuclear translocation
Semiquantitative analysis of subcellular distribution in the absence of aldosterone was performed as previously described (41) . Briefly, cells were transfected with the indicated combination of plasmids and grown for 48 hours in culture medium supplemented with charcoal-stripped serum. Cells were then fixed and mounted and images were taken under a confocal microscope. At least 75 cells per condition were scored into five categories (N, exclusive nuclear localization; N . C, predominant nuclear localization; N = C, even distribution throughout cytosol and nucleus; N , C, predominant cytosolic localization; C, exclusive cytosolic localization). Data are shown as the percentage of cells in each category from the total amount of cells scored. Images were collected using a FluoView 1000 confocal microscope (Olympus, Barcelona, Spain). Kinetic analysis of cortisol-induced MR nuclear translocation was performed as previously described (30, 42) . Briefly, cells were transfected with MR-147-GFP and grown for 48 hours in DMEM supplemented with charcoal-stripped FBS. Cells were then transferred to extracellular saline [137 mm NaCl, 4 mM KCl, 1.8 mM CaCl 2 , 1 mM MgCl 2 , 10 mM glucose, 10 mM HEPES (pH 7.4)], placed under a FluoView 1000 confocal microscope (Olympus) in a temperature-controlled environmental chamber set at 37°C, and treated by adding 10 nM aldosterone to the medium. Images were collected for 60 minutes at a sampling rate of one every 2 minutes. Quantitative analysis of MR-GFP distribution was performed frame by frame using the manufacturer's software (Olympus). Recordings in the absence of aldosterone were performed to control for photobleaching of GFP. Data processing and sigmoid curve fitting were performed using Prism 5 (GraphPad Software, La Jolla, CA) according to the following equation:
where F 0 is the initial nuclear fluorescence, F max is the maximal nuclear fluorescence reached, t 1/2 is the time (minutes) at which fluorescence is halfway between F 0 and F max , and V n is a factor determining how steeply nuclear accumulation changes with time.
In situ PLA PLA was performed using a commercially available kit (Duolink; Olink Biosciences, Uppsala, Sweden) as described (29, 30) . 11b-HSD2 SUMOylation was detected in COS-7 cells transfected with WT or K266R 11b-HSD2-FLAG and YFP-SUMO1 by using a mouse monoclonal anti-FLAG antibody (clone M2; Sigma-Aldrich) and a rabbit polyclonal anti-GFP (Abcam). MR nuclear interaction with SRC-1 coactivator was detected in COS-7 cells transfected with WT MR and SRC-1-HA by using a mouse monoclonal anti-HA antibody (clone HA.11; Covance, Princeton, NJ) and a rabbit polyclonal anti-MR (MR-H300; Santa Cruz Biotechnology). The antibodies used in the assay were previously validated by immunocytochemistry using previously described procedures (31, 41) . Specificity controls consisted of nontransfected cells, cells where one of the transfected plasmids was omitted, or cells not treated with MR ligand. Results were quantified using the software provided by the manufacturer (Duolink Image Tool) and are expressed as average number of puncta per cell area.
Transactivation function assays
MR transcriptional activity was assayed by cotransfecting a plasmid encoding MR with a plasmid containing a synthetic promoter containing two copies of the basic glucocorticoid response element (GRE) fused to the firefly luciferase gene (GRE2X-luc; provided by Dr. Rainer Lanz), and a third plasmid containing Renilla luciferase under the control of a cytomegalovirus promoter (pSG5-ren; provided by Dr. Fátima Gebauer), as previously described (29, 30) . 11b-HSD2 constructs were included in the transfection mix as indicated in each experiment. Total amounts of transfected DNA were kept constant. Cotransfected Renilla and firefly luciferase activities were measured sequentially using a commercially available kit (Dual-Glo; Promega, Madison, WI). MR-dependent transcriptional activity was calculated as the firefly luciferase/Renilla luciferase ratio. Results are given as normalized average 6 standard error (SE). The 50% effective concentration (EC 50 ) values were calculated from normalized data fitted to a log(agonist) vs response equation with variable slope using Prism 5 (GraphPad Software). 11b-HSD2 activity assays 11b-HSD2 enzyme activity was determined using COS-7 cells transfected with WT or non-SUMOylatable mutant K266R complementary DNAs. Cells were washed 24 hours after transfection and then transferred to charcoal-stripped serum-supplemented DMEM. Cells were treated for the indicated time and with the indicated cortisol concentration. Cells were collected for protein assay by the method of Bradford, and medium was used to extract steroids in ethyl acetate [highperformance liquid chromatography (HPLC) grade] for analysis by liquid chromatography-tandem mass spectrometry (LC-MS/ MS). The organic layer was dried by heating at 60°C under a nitrogen gas current. Steroids were then dissolved in mobile phase (30% acetonitrile) and analyzed by LC-MS/MS as per Anderson et al. (43) to obtain the absolute amount of cortisol and cortisone present in the medium. The negative control consisted of samples from nontransfected cells run in parallel. Enzyme activity was calculated as picomoles of cortisone accumulation normalized by time and total amount of protein. In certain experiments we expressed the data as percentage conversion of cortisol to cortisone. Data were fitted to a Michaelis-Menten equation using Prism 5 software (GraphPad Software).
Independently, 11b-HSD2 activity was analyzed by measuring 3 H-corticosterone conversion into 3 H-11-dehydrocorticosterone by HPLC as described (44) . Data were analyzed by measuring the percentage conversion of cortisol to cortisone.
Statistical analysis
Statistical analysis was performed using Prism 5 software (GraphPad Software). An Unpaired Student t test and one-way analysis of variance (ANOVA) followed by Dunn multiple comparison test were used as indicated in each figure.
Results
11b-HSD2 is SUMOylated at lysine 266
We used the prediction algorithm GPS-SUMO (28) to investigate whether the human 11b-HSD2 sequence displays any consensus SUMOylation sites. Results showed that lysine 266 is part of a sequence matching the core SUMOylation consensus motif c-K-x-D/E flanked by P and G residues (Fig. 1A) , which conform a high-probability SUMOylation site (45) . This lysine and the SUMO consensus motif are highly conserved in other mammals, including primates, ruminants, and rodents, but not pigs (Fig. 1A) . Mapping of this residue to a structural homology model of 11b-HSD2, based on the crystal structure of 11b-HSD1 (46) , shows that it lies on a b-sheet exposed to the solution and away from the core of the enzyme containing the catalytic and cofactor binding sites (Fig. 1B) . In addition to the canonical high-probability covalent SUMOylation site surrounding K266, the algorithm predicted additional lower probability SUMOylation sites and SUMO interaction motifs, which may mediate noncovalent interaction with SUMO peptides (Supplemental Table 1 ).
To establish experimentally whether 11b-HSD2 is SUMOylated at residue K266, we cotransfected FLAGtagged WT or K266R mutant 11b-HSD2 with YFP-SUMO1 to perform intramolecular in situ PLA in COS-7 cells. Immunostaining of transfected WT or mutant 11b-HSD2 shows similar distribution patterns consistent with the expected ER-associated localization (6), indicating that mutation K266R does not alter subcellular sorting of the enzyme (Fig. 2A) . PLA results using anti-FLAG and anti-YFP antibodies show a prominent signal suggesting WT 11b-HSD2 SUMOylation in the cytosolic, ER-associated region (Fig. 2B) , even though most of YFP-SUMO-1 protein localizes in the nucleus, as expected (36) . PLA signal of non-SUMOylatable mutant K266R was strongly reduced to ;5% of the WT signal ( Fig. 2B and 2C) . Further support for 11b-HSD2 SUMOylation was obtained by cotransfecting the established deSUMOylase SENP1 (47) . PLA signal was drastically reduced by coexpression of SENP1 to ;20% of the signal ( Fig. 2B and 2C ). Nontransfected cells or omission of either one of the transfected plasmids resulted in the absence of signal ( Fig. 2B and 2C ). These results are consistent with 11b-HSD2 SUMOylation, predominantly at K266 residue.
To confirm 11b-HSD2 SUMOylation at residue K266 and quantify the steady-state fraction of total enzyme showing this posttranslational modification, we cotransfected COS-7 cells with either FLAG-tagged, WT 11b-HSD2 or non-SUMOylatable mutant K266R with a plasmid expressing YFP-SUMO1. Western blot analysis of cell lysates demonstrates comparable expression levels for WT and mutant 11b-HSD2 as well as for YFP-SUMO1 (Fig. 3A) . After immunoprecipitation of 11b-HSD2 with an anti-FLAG antibody and electrophoresis under denaturing conditions, we performed western blots with anti-YFP (to detect YFP-SUMO1) and anti-11b-HSD2. Results obtained with anti-YFP antibody show bands migrating at ;80 kDa (Fig. 3B) , which would be consistent with the predicted molecular mass of ;82.5 kDa resulting from the mass of 11b-HSD2, YFP, and SUMO1 (44, 27, and 11.5 kDa, respectively). The signal was notably decreased in the case of K266R mutant, despite equal levels of total protein expression ( Fig. 3A and 3B) . Probing immunoprecipitation products with anti-11b-HSD2 recognized bands at the predicted 11b-HSD2 molecular mass (44 kDa), indicating that both the WT and mutant forms were immunoprecipitated to comparable extents (Fig. 3C) . Additionally, longer exposure of the blot allowed detecting a slower-migrating band (Fig. 3D ), which coincides with the band detected by anti-YFP at ;80 kDa (Fig. 3B) . Taken together, these results further support that 11b-HSD2 is SUMOylated and that most of the signal arises from modification of residue K266 residue, consistently with results from PLA (Fig. 2) . Interestingly, the larger, SUMOylated form of 11b-HSD2 is not detected when total protein is analyzed by western blot using the input sample (Fig. 3A) . Also, when probing immunoprecipitation products with anti-11b-HSD2 antibody the larger form of 11b-HSD2 requires longer exposure to be detected than the unmodified form (Fig. 3C and 3D ), suggesting that a low proportion of the protein is SUMOylated in our experimental conditions. This is consistent with the general finding that the proportion of proteins modified by SUMO in vivo is very low; however, the modification usually has a high functional impact, a phenomenon that has been termed the "SUMO paradox" (48) .
SUMOylation alters 11b-HSD2 enzyme kinetics but not protein abundance
To assess whether SUMOylation at residue K266 alters 11b-HSD2 enzyme abundance or activity, we transiently transfected WT or mutant 11b-HSD2 in COS-7 cells, quantifying protein expression by western blot. Mutants R213C and R337C, which induce AME in humans, were included as controls. R213C is a loss-of-function mutation (12) , whereas R337C is a destabilized variant of the protein (34, 49) . Quantification of 11b-HSD2 expression in transfected cells showed that nonSUMOylatable mutant K266R or mutation R213C did not produce any significant change in protein abundance when compared with WT 11b-HSD2 (Fig. 4) . As expected, mutant R337C showed clearly diminished expression to ;20% of WT level (Fig. 4) .
To test whether mutation K266R alters 11b-HSD2 activity, we measured conversion of cortisol to cortisone in intact COS-7 cells transfected or not with 11b-HSD2 variants by performing LC-MS/MS on cell extracts. First, we compared the time-dependent conversion of 300 nM cortisol to cortisone in nontransfected or WT 11b-HSD2 transfected cells (Fig. 5A) . Results show a linear time-dependent cortisol conversion in cells transfected with WT 11b-HSD2 and a very slow conversion in nontransfected cells (,1% in up to 4 hours incubation; Fig. 5A ). We then compared WT 11b-HSD2 and non-SUMOylatable mutant K266R activity by incubating 30 minutes with increasing cortisol concentration and fitting the data to a Michaelis-Menten curve (Fig. 5B) . We obtained a K m of 565 6 18 nM for WT and 377 6 13 for K266R mutant and a V max of 574 6 19 pmol/h/mg of protein for WT and 395 6 4 for K266R mutant. The parameters calculated for WT 11b-HSD2 are consistent with previously published data (35, 49) . Differences in enzyme parameters did not reflect differential expression of the 11b-HSD2 constructs (Fig. 4) .
We used an independent method to assess 11b-HSD2 activity by measuring 3 H-corticosterone conversion to 3 H-11-dehydrocorticosterone by HPLC. COS-7 cells were treated with 10 nM H-11-dehydrocorticosterone was measured and normalized to total protein content. WT 11b-HSD2 showed a 12.24% (60.55) conversion (mean 6 SE, n = 6), whereas mutant K266R showed a 12.72% (60.43) conversion (n = 6).
Lack of SUMOylation at residue K266 allows cortisol-dependent MR nuclear translocation
To investigate whether K266 SUMOylation has a role on 11b-HSD2 function in diminishing MR activation by glucocorticoids, we first asked whether mutant K266R affects 11b-HSD2 ability to prevent cortisol-induced MR nuclear translocation. To that end, we studied nuclear translocation of our fully functional fluorescent derivative MR, with YFP inserted after amino acid 147 (29-31), cotransfected or not with different 11b-HSD2 constructs fused to CFP (WT; AME loss-of-function mutant R337C; and non SUMOylatable mutant K266R). The assay was performed in COS-7 cells, which lack detectable endogenous expression of 11b-HSD2 (Figs. 2, 4 , and 5). Transfected cells were left untreated or exposed overnight to two different physiological cortisol concentrations (100 or 500 nM). In the absence of ligand, MR localization is predominantly cytosolic in most (.80%) of the cells (Fig. 6A and 6B ), as previously described in the same cell line (50) . Cotransfection with WT 11b-HSD2, K266R, or R337C did not alter naive MR subcellular localization in the absence of cortisol (Fig. 6A  and 6B ). Overnight treatment with 100 nM cortisol stimulated full MR translocation to the nucleus (.90% of cells). WT 11b-HSD2 coexpression prevented MR translocation, keeping a predominantly cytosolic MR localization, consistent with the cortisol-inactivation function of the enzyme (Fig. 6C and 6D) . Cotransfection of the 11b-HSD2-R337C construct failed to prevent cortisol-induced MR translocation (Fig. 6C and 6D) , consistent with the loss-of-function effect previously described for this AME mutant (34) . Non-SUMOylatable mutant 11b-HSD2-K266R coexpression was also unable to prevent MR nuclear translocation induced by 100 nM cortisol, behaving similar to the loss-of-function mutant R337C (Fig. 6C and 6D) . Overnight exposure to 500 nM cortisol resulted in MR full nuclear translocation in all conditions ( Fig. 6E and 6F ). This demonstrates that 11b-HSD2 capacity to inactivate cortisol can be exceeded by high cortisol levels at the high end of the physiological range, consistent with previous data (6, 44) .
Because lysine residues are the target of other posttranslational modifications in addition to SUMOylation, the effect of the K266R mutant on cortisol-induced MR translocation could reflect other actions, including acetylation or ubiquitination. To assess this, we coexpressed WT 11b-HSD2 with the established deSUMOylase SENP1. This experiment also resulted in full cortisol-induced MR translocation, consistent with a SUMOylation-mediated effect on the ability of 11b-HSD2 to prevent cortisol access to MR (Fig. 6G and 6H ). Note that MR has also been described to be SUMOylated in cells (51) . Our experiment indicates that if MR is SUMOylated under our experimental conditions, SENP1-mediated removal of SUMO does not prevent cortisol-induced receptor nuclear translocation.
We next investigated the kinetics of cortisol-induced nuclear translocation in living COS-7 cells by imaging MR subcellular dynamics for the first hour after 100 nM cortisol addition. We ran time-lapse experiments in cells cotransfected with MR-147-GFP with or without WT 11b-HSD2, AME mutant R337C, or non-SUMOylatable mutant K266R. All 11b-HSD2 constructs used were CFP tagged. Images were taken every 2 minutes up to 60 minutes after ligand addition, and the ratio of nuclear MR was calculated for every frame. Full cortisol-dependent MR nuclear translocation was achieved ;50 minutes after ligand addition (Fig. 7) . As expected, WT HSD2 prevented nuclear import (,10% of the receptor translocated over the time period). MR translocation in the presence of AME mutant R337C or non-SUMOylatable mutant K266R was indistinguishable from the control MR condition (Fig. 7) . These data are consistent with subcellular localization after overnight treatment (Fig. 6C and 6D) , suggesting that 11b-HSD2 ability to prevent cortisol-induced MR translocation is regulated by SUMOylation of lysine 266.
11b-HSD2-K266R decreases cortisol-but not aldosterone-dependent MR transcriptional response
We then tested whether MR-mediated gene transactivation is affected by 11b-HSD2 SUMOylation. MR activity was assessed in COS-7 cells by cotransfecting the receptor with a luciferase reporter gene under the control of a promoter with two GREs (GRE2X). We treated cells overnight with increasing doses of cortisol in the presence or absence of the different 11b-HSD2 constructs. An MR cortisol-dependent transactivation curve showed an EC 50 of 40 nM (Fig. 8A) . AME mutants 11b-HSD2-R337C or R213C did not alter cortisol potency to elicit MR-dependent transactivation, presenting an EC 50 of 32-44 nM, as expected for loss-of-function constructs. The presence of WT 11b-HSD2 produced the expected decrease in cortisol potency and MR maximal response, with an EC 50 of ;2 mM, two orders of magnitude higher than cortisol EC 50 for MR. Surprisingly, non-SUMOylatable mutant 11b-HSD2-K266R also decreased cortisol EC 50 (1.4 mM) and MR maximal response, behaving similar to WT 11b-HSD2 (Fig. 8A) . Western blot analysis showed that results of activity assays are not due to impaired MR expression ( Fig. 8C and 8D) .
Taking into consideration the experiments described earlier, it is clear that 11b-HSD2-K266R promotes nuclear MR translocation by cortisol but does not alter its dose dependence for transactivation (compare Figs. 6C  and 8A ). This may suggest that MR is functionally impaired in the presence of 11b-HSD2-K266R. Therefore, we tested aldosterone-dependent MR transactivation with the different 11b-HSD2 constructs (Fig. 8B) . All dose-response curves were superimposed, with an EC 50 of ;0.1-0.2 nM, as expected for aldosterone (32) . This result demonstrates that 11b-HSD2-K266R does not impede MR activation per se.
11b-HSD2 SUMOylation affects cortisol-dependent recruitment of coactivators to MR
To gain insight into the mechanism by which 11b-HSD2-K266R prevents cortisol-induced MR transactivation, we tested the interaction between MR and SRC-1, a well-known coactivator of MR (52) . We cotransfected COS-7 cells with WT MR and SRC1 tagged with an HA epitope. SRC-1 displays a predominantly nuclear localization both in control and cortisolstimulated conditions, whereas MR shows the expected ligand-induced trafficking from cytosol to nucleus (Fig. 9A) . To quantitatively assess MR-SRC-1 interaction we used PLA in cells coexpressing these two proteins with CFP-tagged WT 11b-HSD2 or K266R mutant. Results show a prominent PLA signal in the nucleus when MR is cotransfected with SRC-1 and nuclear translocation is promoted by cortisol (Fig. 9B) . PLA signal was reduced to ;40% by coexpression of either WT or K266R 11b-HSD2 (Fig. 9B and 9C) . Nontransfected cells, omission of either one of the transfected plasmids, or no ligand addition resulted in the absence of signal (Fig. 9B and 9C ). To ensure that decreased PLA signals did not arise from altered protein expression levels, we quantified MR, SRC-1, and 11b-HSD2 abundance by western blot. This experiment showed that coexpression of the three different proteins did not affect their relative levels ( Fig. 9D and  9E ). These results demonstrate that efficient interaction of MR with SRC-1 is impaired not only by the presence of active 11b-HSD2 (which decreases MR nuclear translocation through cortisol inactivation) but also by the non-SUMOylatable mutant K266R.
Discussion
Our results show that 11b-HSD2 is modified by SUMOylation, with a key conjugation site at residue K266, which is part of a canonical consensus SUMO conjugation site. The posttranslational modification likely affects a small percentage of the total cellular protein. This does not preclude an effect on the biology of 11b-HSD2, because it is a common observation that a small fraction of steady-state SUMOylation frequently has important consequences on the total cellular pool of the modified protein (48) . This idea is reinforced by the fact that SENP1 coexpression with WT 11b-HSD2 reproduces the effect seen with mutant K266R. The implication is that SUMO modification likely alters substrate proteins long after deconjugation, perhaps by modifying the protein environment where they reside. This may have implications for the functional observations reported in this study, as we discuss below. The effect of K266 modification on 11b-HSD2 enzymatic activity appears to be mild, with a 30% decrease in V max that is not attributable to decreased protein expression. According to structural homology modeling using as a template the crystal structure of 11b-HSD1 (46) or 17b-HSD1 (53), residue K266 lies exposed to the surface of the enzyme (Fig. 1B) . This area is not directly involved in ligand or cofactor binding regions and does not form part of the enzyme dimerization interphase. Therefore, it is not surprising that, unlike the AME mutations affecting those regions (53) , SUMOylation at residue K266 does not dramatically alter enzyme activity. Alternatively, the effect of mutant K226R is reminiscent of a mutation in a nearby residue, R279C, which produces a mild form of AME and displays a reduction of ;33% in V max without changes in K m (54) . Therefore, it is clear that even a rather small change in enzyme kinetics not affecting K m is able to diminish the efficiency of 11b-HSD2 to prevent glucocorticoid-induced MR activation.
Despite only a mild effect on enzyme kinetics, the consequence of K266R mutation or enzymatic SUMO deconjugation on the ability of cortisol to translocate MR to the nucleus is striking. It is clear that regardless of measurable enzymatic activity, only 11b-HSD2 that can be SUMOylated appears to be able to prevent cortisol from inducing MR translocation to the nucleus. However, what is even more surprising is that MR translocated under those conditions (lack of 11b-HSD2 SUMOylation at residue K266) does not increase transactivation of a target promoter, indicating that there is a strong dissociation between MR subcellular localization and activity. To better understand the relationship between MR nuclear translocation and activity, we generated combined plots where both parameters can be visualized together (Fig. 10 ). This analysis clearly shows that MR ligand dependence for nuclear translocation is left shifted when compared with ligand dependence for transactivation, particularly in the case of cortisol, both in the absence or presence of 11b-HSD2 (compare Fig. 10B and 10C) . Lack of SUMOylation in 11b-HSD2-K266R makes the difference in ligand dependence of both processes even more prominent (Fig. 10D) . In fact, data obtained in vivo already suggest this difference. In a detailed study examining subcellular localization of MR and GR in rat kidney under different corticosteroid circulating levels, Ackermann et al. (55) provided evidence to suggest that 11b-HSD2 is sufficient to prevent glucocorticoid-induced GR translocation to the nucleus, but not MR. Therefore, under physiological onditions, enough glucocorticoids escape 11b-HSD2 action to translocate MR to the nucleus, but not to overly activate the receptor and produce excessive Na + reabsorption. This fits well with data showing that under physiological conditions 11b-HSD2 activity cannot prevent most of epithelial MR being occupied by glucocorticoids (56), but somehow is able to lock glucocorticoid/ MR complexes in an inactive state (57) . It has been proposed that 11b-HSD2-dependent production of NADH could be involved in this phenomenon. According to this hypothesis, decreased 11b-HSD2 activity would reduce NADH cellular levels and consequently unlock glucocorticoid/MR activity. It may be that 11b-HSD2 SUMOylation alters the coupling of metabolic processes with glucocorticoid-dependent MR translocation, although our data do not allow assessing this possibility.
Taken together, our data suggest that lack of 11b-HSD2 SUMOylation dissociates MR subcellular localization and activity, allowing cortisol-induced nuclear translocation without generating the conformation necessary to recruit transcriptional coactivators. We speculate that 11b-HSD2 may be interacting directly or indirectly with MR, allowing a cortisol-mediated conformational change of the receptor that participates in its activation and depends on previous 11b-HSD2 modification by SUMOylation. This would be in agreement with the proposed function of SUMOylation of altering the environment where the modified protein interacts even after removal of SUMO (48) . Could SUMOylation Figure 10 . Ligand dose-dependence regulation of MR nuclear translocation and activity. Plots simultaneously represent relative luciferase (luc) activity and percentage nuclear MR localization for the indicated ligand concentration and in the presence or absence of WT or mutant 11b-HSD2. Data points were fitted to a variable slope model (four parameters). Individual data points or bars represent mean 6 SE. Nuclear localization data at 0, 100, and 500 nM cortisol come from Fig. 6 . Luciferase activity data come from Fig. 8 .
alter the proposed physical interaction between MR and 11b-HSD2, previously suggested in the literature (6)? This hypothesis implies that adequate interaction between MR and 11b-HSD2 is necessary for the correct cortisol-induced conformational change of the receptor required to recruit transcriptional coactivators. In the absence of SUMOylation, this interaction would be altered, decreasing MR transcriptional efficiency, but increasing its ability to translocate to the nucleus. Based on this idea, we checked whether we could detect direct interaction between MR with 11b-HSD2 by PLA, but the results were negative (data not shown). This suggests that MR and 11b-HSD2 may not closely interact in the cell, although the result does not preclude the possibility that both proteins are part of a larger complex and that SUMOylation of 11b-HSD2 alters the nature of it. Additionally, note that one of us (A.O.) has also performed two-hybrid assays and coimmunoprecipitation experiments that failed to see a direct interaction between MR and 11b-HSD2. A putative bridging protein may exist but has not been identified yet.
A different explanation for our data could be based on a compartmentalization of the effects of 11b-HSD2 on cortisol concentration in the cell. Under this scenario, lack of 11b-HSD2 SUMOylation would change MR subcellular localization, shifting it toward the nucleus, but nuclear MR would still be depleted of cortisol because of the enzymatic activity of 11b-HSD2. For instance, it is conceivable that 11b-HSD2 SUMOylation could place the enzyme near the nuclear pore, creating a low-cortisol nanodomain. SUMO-dependent targeting of proteins to the nuclear pore localization has been previously described (58) . Disruption of this localization could favor MR nuclear localization without changing the bulk concentration of cortisol in the cell. Further work is needed to address this hypothesis.
It remains to be explained why the dissociation between cortisol-dependent nuclear localization and transcriptional activity is larger than that detected with aldosterone ( Fig. 10A and 10B ). It has been demonstrated that cortisol and aldosterone induce differential conformational changes in MR upon binding. For instance, both agonists differ in their ability to induce interdomain interactions between the NH 2 -and COOH-terminal domains of MR (59) . We suggest that aldosterone ability to stabilize the ligand binding domain of the receptor is enough to allow the correct conformational change, regardless of previous functional or physical interaction with 11b-HSD2, whereas cortisol is unable to do so, due in part to the higher off-rate previously reported (44) and to the influence of non-SUMOylated 11b-HSD2.
In summary, we have shown that 11b-HSD2 is SUMOylated and that this modification mainly takes place at residue K266. Mutation of this residue mildly affects enzyme activity by slightly enhancing substrate affinity and lowering V max , but dramatically alters 11b-HSD2 ability to prevent cortisol-induced MR nuclear translocation. Interestingly, although impairing 11b-HSD2 SUMOylation enhances cortisol-dependent MR nuclear translocation, the amount of MR/coactivator complexes formed remains unaltered, resulting in the same transcriptional activity. This phenomenon uncovers a complex and SUMOylation-regulated functional role of 11b-HSD2 that dissociates glucocorticoid-dependent MR subcellular localization from transcriptional activity.
